ROYAL BLUE SKY BLUE 283 PET X ET7300-0021 H Natural

TRANS BLUE WATER BLUE SG 6212-21-H

P-9048 H MED DK FLINT BLUE 541C PE DC BLUE METALLIC

Each cradle brace is a two-foot long, rectangular bar with a “U” shape machined into each end for a metallic insert.

Each cradle brace is a two-foot long, rectangular bar with a “U” shape machined into each end for a metallic insert.

Each cradle brace is a two-foot long, rectangular bar with a “U” shape machined into each end for a metallic insert.

D is t. ) K W R R P M P P G A V Y F U L G C P H X L F M C F O E IF F H U N E C L A S H E M N K R A C E S C L G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of June 4, 2021 Avient reflects 2021 estimated revenue of $4,300M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 78% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of June 4, 2021 87 89 87 86 83 81 76 88 85 83 82 81 80 78 78 78 76 72 71 69 50 18 A vi en t K W R P P G R P M A V Y F U L G C P F M C H X L U N V R IF F E C L A S H F O E C E E M N B N R H U N G R A K R A S C L A L B Source: Peer data per Bloomberg market data as of June 4, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 28 Avient reflects 2021 estimated EBITDA of $560M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 10.4 18.2 16.0 15.5 15.3 11.3 11.0 29.7 26.5 23.5 18.2 13.4 11.9 11.9 11.7 10.5 10.4 10.3 10.1 9.7 7.7 6.5 A vi en t K W R A V Y P P G R P M F U L G C P H X L A L B E C L IF F F M C B N R A S H G R A E M N F O E S C L U N V R C E K R A H U N Median: 11.7xMedian: 15.4x SUMMARY: WHY INVEST IN AVIENT?

B ij la ge n bi j he t B el gi sc h St aa ts bl ad - 3 0/ 11 /2 02 1 - A nn ex es d u M on it eu r be lg e

STAN-TONE HCC-33865 BLUE H ORANGE METALLIC 66987GNS FAST FILMS BLUE

WHITE H CAP DR101 INK BLUE DARK BLUE